Amicus Therapeutics, Inc. (Nasdaq: FOLD) reports a Q1 non-GAAP loss of $0.28, 10 cents better than the analyst estimate of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE